Cargando…

Combination of palbociclib and radiotherapy for glioblastoma

The cyclin-dependent kinase inhibitor, palbociclib has shown compelling efficacy in breast cancer patients. Several pre-clinical studies of glioblastoma (GBM) have also shown palbociclib to be efficacious. In this study, we investigated palbociclib in combination with radiation therapy (RT) for trea...

Descripción completa

Detalles Bibliográficos
Autores principales:	Whittaker, Shane, Madani, Daniel, Joshi, Swapna, Chung, Sylvia A, Johns, Terrance, Day, Bryan, Khasraw, Mustafa, McDonald, Kerrie L
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group 2017
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5494656/ https://www.ncbi.nlm.nih.gov/pubmed/28690875 http://dx.doi.org/10.1038/cddiscovery.2017.33

Ejemplares similares

Veliparib in combination with radiotherapy for the treatment of MGMT unmethylated glioblastoma
por: Jue, Toni Rose, et al.
Publicado: (2017)

Ibudilast sensitizes glioblastoma to temozolomide by targeting Macrophage Migration Inhibitory Factor (MIF)
por: Ha, Wendy, et al.
Publicado: (2019)

The evolving roles and controversies of radiotherapy in the treatment of glioblastoma
por: Hau, Eric, et al.
Publicado: (2016)

A randomized phase II trial of veliparib, radiotherapy, and temozolomide in patients with unmethylated MGMT glioblastoma: the VERTU study
por: Sim, Hao-Wen, et al.
Publicado: (2021)

Updates on managing advanced breast cancer with palbociclib combination therapy
por: McShane, Teresa M., et al.
Publicado: (2018)

Unexpected toxicity of CDK4/6 inhibitor palbociclib and radiotherapy
por: van Aken, Evert S. M., et al.
Publicado: (2021)

A case study of a long-term glioblastoma survivor with unmethylated MGMT and hypermutated genotype
por: Jue, Toni Rose, et al.
Publicado: (2019)

Dual-targeting of aberrant glucose metabolism in glioblastoma
por: Shen, Han, et al.
Publicado: (2015)

The effects of palbociclib in combination with radiation in preclinical models of aggressive meningioma
por: Horbinski, Craig, et al.
Publicado: (2021)

Two Novel Palbociclib-Resorcinol and Palbociclib-Orcinol Cocrystals with Enhanced Solubility and Dissolution Rate
por: Duan, Chenxin, et al.
Publicado: (2021)

Palbociclib-Induced Liver Failure
por: Atallah, Rami, et al.
Publicado: (2020)

Role of Biomarkers in the Clinical Management of Glioblastomas: What are the Barriers and How Can We Overcome Them?
por: McDonald, Kerrie L., et al.
Publicado: (2013)

CDK4/6 Inhibitor PD0332991 in Glioblastoma Treatment: Does It Have a Future?
por: Schröder, Lisette B. W., et al.
Publicado: (2015)

Palbociclib in combination with simvastatin induce severe rhabdomyolysis: a case report
por: Nersesjan, Vardan, et al.
Publicado: (2019)

Combination of Talazoparib and Palbociclib as a Potent Treatment Strategy in Bladder Cancer
por: Klein, Florian G., et al.
Publicado: (2021)

Anoctamins and Calcium Signalling: An Obstacle to EGFR Targeted Therapy in Glioblastoma?
por: Dewdney, Brittany, et al.
Publicado: (2022)

For whom the T cells troll? Bispecific T-cell engagers in glioblastoma
por: Singh, Kirit, et al.
Publicado: (2021)

Radiotherapy combined with nivolumab or temozolomide for newly diagnosed glioblastoma with unmethylated MGMT promoter: An international randomized phase III trial
por: Omuro, Antonio, et al.
Publicado: (2022)

Combined Androgen receptor blockade overcomes the resistance of breast cancer cells to palbociclib
por: Ji, Wenfei, et al.
Publicado: (2019)

Palbociclib in the treatment of recurrent ovarian cancer
por: Lee, Dai Wee, et al.
Publicado: (2020)

Palbociclib in breast cancer neoadjuvant setting
por: Duarte, Sílvia Alexandra Cabral, et al.
Publicado: (2021)

The role of TP53 gain-of-function mutation in multifocal glioblastoma
por: Olafson, Lauren R., et al.
Publicado: (2020)

Improve BBB Penetration and Cytotoxicity of Palbociclib in U87-MG Glioblastoma Cells Delivered by Dual Peptide Functionalized Nanoparticles
por: Lo, Yu-Chen, et al.
Publicado: (2023)

Safety of palbociclib concurrent with palliative pelvic radiotherapy: discussion of a case of increased toxicity and brief review of literature
por: Dasgupta, Archya, et al.
Publicado: (2020)

Targeting Immunometabolism in Glioblastoma
por: Mohan, Aditya A., et al.
Publicado: (2021)

Optimising Outcomes for Glioblastoma through Subspecialisation in a Regional Cancer Centre
por: Back, Michael, et al.
Publicado: (2018)

Cytotoxic lanthanum oxide nanoparticles sensitize glioblastoma cells to radiation therapy and temozolomide: an in vitro rationale for translational studies
por: Lu, Victor M., et al.
Publicado: (2020)

Clinical efficacy and mechanism of Pralatrexate combined with Palbociclib Isethionate in treatment of bladder cancer patients
por: Wang, Xiaobin, et al.
Publicado: (2019)

Severe toxic rhabdomyolysis under combined palbociclib and simvastatin treatment: A case report
por: Poumeaud, François, et al.
Publicado: (2022)

Radiotherapy-drug combinations in the treatment of glioblastoma: a brief review
por: McAleavey, Patrick G, et al.
Publicado: (2022)

Therapeutic Potential of Linearol in Combination with Radiotherapy for the Treatment of Glioblastoma In Vitro
por: Zoi, Vasiliki, et al.
Publicado: (2023)

Combined anti-C1-INH and radiotherapy against glioblastoma
por: Liljedahl, Emma, et al.
Publicado: (2023)

Profile of palbociclib in the treatment of metastatic breast cancer
por: Ehab, Moataz, et al.
Publicado: (2016)

Neutropenia due to palbociclib: A word of caution?
por: Pramanik, Raja, et al.
Publicado: (2016)

Palbociclib: COVID-19 infection: case report
Publicado: (2020)

Lysosomal trapping of palbociclib and its functional implications
por: Llanos, Susana, et al.
Publicado: (2019)

Palbociclib: Myelosuppression and gastrointestinal reactions: case report
Publicado: (2022)

Advances in Radiotherapy for Glioblastoma
por: Mann, Justin, et al.
Publicado: (2018)

In vitro evaluation of photon and carbon ion radiotherapy in combination with chemotherapy in glioblastoma cells
por: Combs, Stephanie E, et al.
Publicado: (2012)

Global phosphoproteomics reveals DYRK1A regulates CDK1 activity in glioblastoma cells
por: Recasens, Ariadna, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_9fuec87gl3g7qt1h789brucctj